A new study led by researchers at the UNC School of Medicine and Cartesian Therapeutics, found that immunotherapy can help ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions Am J Manag Care. 2025;31(Spec. No. 13 ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...

ASH 2025 data on KLN-1010 suggest that off-the-shelf, in vivo CAR T therapy could significantly expand access to cellular ...

Early evidence suggests safety, efficacy, while awaiting data on durability in broader pop ...

Cipla has partnered with ImmunoACT to introduce the CAR-T cell therapy 'talicabtagene autoleucel' in South Africa, Algeria, ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...